rethinkTHC Search
Menu
Study breakdown

Nabilone may help agitation in dementia but there is no convincing evidence that cannabinoids help cognition

Systematic ReviewPreliminary evidence
The takeaway

A systematic review of five trials found nabilone may reduce agitation in dementia patients, but THC showed no significant benefit for agitation and no studies tested cannabinoids for cognitive decline.

Families of dementia patients, geriatric psychiatrists, dementia researchers

Nabilone may help agitation but no cannabinoid has been shown to help dementia cognition

What the researchers found

Nabilone (1-2 mg/day) showed significant improvement in agitation in one trial. THC (1.5-4.5 mg/day) showed no significant differences from placebo for agitation in two trials. Dronabinol (5 mg/day) improved weight in one anorexia-focused trial. No studies examined cannabinoids for cognitive symptoms.

Why it matters

With dementia patients and families seeking new treatment options, this review provides a clear picture: there is a thin line of evidence for nabilone in agitation but essentially no support for cannabinoids improving cognition or disease progression.

The numbers in context

5 RCTs included; nabilone 1-2 mg/day improved agitation; THC 1.5-4.5 mg/day no benefit for agitation; dronabinol 5 mg/day improved weight; 0 studies on cognitive decline; evidence rated low to very low

How the study worked

Systematic review following PRISMA guidelines, searching Medline, Embase, Cochrane, and PsycINFO. Five randomized controlled trials met inclusion criteria.

What this study cannot tell us

Only five trials with low to very low quality evidence. Small sample sizes. Different cannabinoid preparations tested. No studies on cognitive outcomes. Short follow-up periods.

How to read the evidence

Systematic review with low to very low quality evidence from five small trials

When this study was published

Published in 2021. The evidence base for cannabinoids in dementia remains extremely limited.

The bigger picture

The distinction between nabilone (synthetic, possibly effective for agitation) and THC (natural, no clear benefit) suggests that different cannabinoids may have very different utility in dementia, and lumping them together is unhelpful.

Questions still open

  • Why did nabilone succeed where THC failed for agitation? Should future trials focus exclusively on nabilone for behavioral symptoms? Would CBD, which has not been tested for dementia, show different results?

Common questions

Can cannabinoids help with dementia?
One trial found the synthetic cannabinoid nabilone may reduce agitation. However, natural THC showed no benefit for agitation, and no studies have tested any cannabinoid for cognitive decline in dementia.
Should dementia patients try cannabis?
Based on current evidence, it may be too early to recommend cannabinoids for dementia. Nabilone shows some promise for agitation specifically, but the evidence is rated low quality and more research is needed.

Read the original research

Effectiveness of Cannabinoids for Treatment of Dementia: A Systematic Review of Randomized Controlled Trials.

Clinical gerontologist, 44(1), 16-24

Citation

Charernboon, Thammanard; Lerthattasilp, Tiraya; Supasitthumrong, Thitipon. (2021). Effectiveness of Cannabinoids for Treatment of Dementia: A Systematic Review of Randomized Controlled Trials.. Clinical gerontologist, 44(1), 16-24. https://doi.org/10.1080/07317115.2020.1742832

Explore the wider topic